| Bioactivity | CAP-53194 is a selective Plk1 inhibitor with potential anticancer activity. CAP-53194 was identified by a high-throughput virtual screening approach using molecular docking, showing 100-fold selectivity for Plk1 over Plk2-4 and other cell cycle kinases. CAP-53194 is able to effectively exploit subtle differences between the binding sites of Plk1 and other Ser/Thr kinases, thereby enhancing their inhibitory effects. CAP-53194 meets the Lipinski compound analog criteria and passes other ADMET filters, indicating good compound compatibility. CAP-53194 belongs to a new class of potential Plk1 inhibitors suitable for subsequent compound development and testing[1]. |
| CAS | 660817-08-3 |
| Formula | C21H14N6O5 |
| Molar Mass | 430.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach |
CAP-53194
CAS: 660817-08-3 F: C21H14N6O5 W: 430.37
CAP-53194 is a selective Plk1 inhibitor with potential anticancer activity. CAP-53194 was identified by a high-throughpu
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.